Tybourne Capital Management (Hk) LTD has filed its 13F form on May 15, 2025 for Q1 2025 where it was disclosed a total value porftolio of $23.6 Billion distributed in 5 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Acelyrin Inc (Slrn Us) with a value of $7.18B, Taysha Gene Therapies, Inc. with a value of $5.14B, Bicycle Therapeutics PLC with a value of $4.89B, Forte Biosciences Inc (Fbrx Us) with a value of $4.81B, and Zentalis Pharmaceuticals, Inc. with a value of $1.53B.

Examining the 13F form we can see an increase of $23.2B in the current position value, from $315M to 23.6B.

Tybourne Capital Management (Hk) LTD is based out at Hong Kong, K3

Below you can find more details about Tybourne Capital Management (Hk) LTD portfolio as well as his latest detailed transactions.

Portfolio value $23.6 Billion
Healthcare: $11.6 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 5
  • Current Value $23.6 Billion
  • Prior Value $315 Million
  • Filing
  • Period Q1 2025
  • Filing Date May 15, 2025
  • Form Type 13F-HR
  • Activity in Q1 2025
  • New Purchases 0 stocks
  • Additional Purchases 0 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 1 stocks
Track This Portfolio

Track Tybourne Capital Management (Hk) LTD Portfolio

Follow Tybourne Capital Management (Hk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.